Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

121. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

122. Adalimumab - Psoriasis

Adalimumab - Psoriasis Common Drug Review CEDAC Meeting – September 17, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – October 16, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB (Humira ® – Abbott Laboratories Ltd.) NEW INDICATION: PSORIASIS Description: Adalimumab is a human monoclonal antibody tumour necrosis factor (TNF). The basis of this resubmission is a new indication. Adalimumab is indicated for the treatment of adult patients (...) with chronic moderate to severe psoriasis who are candidates for systemic therapy. For patients with chronic moderate plaque psoriasis, adalimumab should be used after phototherapy has been shown to be ineffective or inappropriate. Previous CEDAC Recommendations for Adalimumab: • Rheumatoid arthritis (see Notice of CEDAC Final Recommendation, February 11, 2005) • Psoriatic arthritis (see Notice of CEDAC Final Recommendation, November 29, 2006) • Ankylosing spondylitis (see Notice of CEDAC Final

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

123. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two (Abstract)

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two To evaluate the efficacy and safety of the tumor necrosis factor (TNF) antagonist adalimumab in patients with axial spondylarthritis (SpA) without radiographically defined sacroiliitis refractory to conventional treatment.Patients with active axial SpA (...) (n = 46) were randomized to receive placebo or adalimumab at a dosage of 40 mg subcutaneously every other week for 12 weeks, followed by an open-label extension that continued up to week 52. The diagnosis of axial SpA required the presence of 3 of 6 diagnostic criteria, including 2 of the following 3 criteria: inflammatory back pain, HLA-B27 positivity, or acute inflammation of the spine or sacroiliac joints on magnetic resonance imaging, in the absence of radiographic evidence of sacroiliitis

2008 EvidenceUpdates Controlled trial quality: predicted high

124. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial (Abstract)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis.We sought to evaluate clinical efficacy and safety of adalimumab for moderate to severe psoriasis and investigate continuous versus interrupted therapy.We conducted a 52-week, multicenter study of 1212 patients randomized to receive adalimumab (40 mg (...) ) or placebo every other week for the first 15 weeks. At least 75% improvement in the Psoriasis Area and Severity Index (PASI) score was the criterion for advancement through this multiphase study.At week 16, 71% (578 of 814) of adalimumab- and 7% (26 of 398) of placebo-treated patients achieved greater than or equal to 75% improvement in the PASI score. During weeks 33 to 52, the percentage of patients rerandomized to placebo who lost adequate response (defined as <50% improvement in the PASI response

2008 EvidenceUpdates Controlled trial quality: uncertain

125. Adalimumab for the treatment of adults with psoriasis (TA146)

Adalimumab for the treatment of adults with psoriasis (TA146) Overview | Adalimumab for the treatment of adults with psoriasis | Guidance | NICE Adalimumab for the treatment of adults with psoriasis Technology appraisal guidance [TA146] Published date: 25 June 2008 Share Guidance on adalimumab (Humira) for treating psoriasis in adults. Since this guidance was published, an equality consideration has been raised about the PASI instrument. When using the Psoriasis Area Severity Index (PASI (...) ), healthcare professionals should take into account skin colour and how this could affect the PASI score, and make the clinical adjustments they consider appropriate. The recommendations also apply to adalimumab biosimilar products that have a marketing authorisation allowing the use of the biosimilar for the same indication. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

126. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143) Adalimumab, etanercept and infliximab for ankylosing spondylitis | Guidance | NICE Adalimumab, etanercept and infliximab for ankylosing spondylitis Technology appraisal guidance [TA143] Published date: 28 May 2008 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

127. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. Full Text available with Trip Pro

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis.Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification (...) according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks. We randomly assigned patients with an American College of Rheumatology Pediatric 30% (ACR Pedi 30) response at week 16 to receive adalimumab or placebo in a double-blind fashion every other week for up to 32 weeks.Seventy-four percent of patients not receiving methotrexate (64 of 86) and 94% of those receiving methotrexate (80 of 85) had

2008 NEJM Controlled trial quality: predicted high

128. Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease

Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Article Text

2008 Evidence-Based Medicine

129. Adalimumab - Crohn's disease

Adalimumab - Crohn's disease Common Drug Review CEDAC Meeting – November 21, 2007 Page 1 of 3 Notice of CEDAC Final Recommendation – December 19, 2007 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB RESUBMISSION #3 (Humira ® – Abbott Laboratories Ltd.) Description: Adalimumab is a human monoclonal antibody to tumour necrosis factor (TNF). The Canadian Expert Drug Advisory Committee (CEDAC) previously reviewed adalimumab for rheumatoid arthritis (see CEDAC Final (...) Recommendation on Adalimumab, February 11, 2005), psoriatic arthritis (see CEDAC Final Recommendation, November 29, 2006) and ankylosing spondylitis (see CEDAC Final Recommendation, June 27, 2007). A new indication for use in Crohn’s disease was the basis for this resubmission. Adalimumab is approved for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

130. Adalimumab - Arthritis, rheumatoid

Adalimumab - Arthritis, rheumatoid CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB (Humira™--Abbott Laboratories, Limited) Description: Adalimumab is indicated for reducing the signs and symptoms, and inhibiting the progression of structural damage, in adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be used alone or in combination (...) with methotrexate or other DMARDs. Recommendation: CEDAC recommends that adalimumab be listed for patients with moderate to severe active RA who meet current drug plan criteria for funding of infliximab or etanercept (i.e. patients must be refractory to or intolerant of at least two potent DMARDs, including methotrexate and leflunomide). The number of doses should be limited to twenty-six 40 mg doses per year with no dose escalation permitted. Adalimumab should not be used in combination with other tumor

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

131. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis | Guidance | NICE Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis Technology appraisal guidance [TA130] Published date: 22 October 2007 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2007 National Institute for Health and Clinical Excellence - Technology Appraisals

132. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill R A, Jones A, Mujica Mota R, Walley T CRD summary (...) This review, which assessed the clinical effectiveness of anti-tumour necrosis factor-α therapy for patients with ankylosing spondylitis, concluded that the therapy is clinically effective in the short term. The authors' conclusions are likely to be reliable. Authors' objectives To assess the comparative clinical effectiveness and cost-effectiveness of anti-tumour necrosis factor (TNF)-α therapy (adalimumab, etanercept and infliximab) for the treatment of ankylosing spondylitis. This abstract will only

2007 DARE.

133. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review Full Text available with Trip Pro

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response (...) in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T CRD summary This review compared tumour necrosis factor-alpha blocking drugs for rheumatoid arthritis and concluded that adalimumab, etanercept and infliximab had similar efficacy, but infliximab may need higher doses for a similar effect. Given that this was based on an indirect comparison of only one trial of each

2007 DARE.

134. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness

Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis (...) and review of comparative clinical- and cost-effectiveness Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis

2007 Health Technology Assessment (HTA) Database.

135. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technology Assessment 2007; 11(28): 1-158 Authors' objectives "The objectives of this review were to assess the comparative clinical effectiveness

2007 Health Technology Assessment (HTA) Database.

136. Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing

Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing National Horizon Scanning Centre Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation National Horizon Scanning Centre. Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2007 Authors' objectives This study examines the use of Adalimumab (Humira) for juvenile idiopathic arthritis. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Arthritis, Juvenile Rheumatoid /drug therapy Language Published English Country of organisation England Address

2007 Health Technology Assessment (HTA) Database.

137. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Full Text available with Trip Pro

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Walsh C A, Minnock P, Slattery C, Kennedy N, Pang F, Veale D J, Bresnihan B, FitzGerald (...) ' therapy) to adalimumab. The mean infliximab dosage was 5 mg/kg every 8 weeks. When patients were switched to adalimumab they received 40 mg subcutaneously every other week. One-year extrapolation data were also presented. Type of intervention Treatment. Economic study type Cost-effectiveness analysis Study population Eligible individuals were those with RA and responders to at least 12 weeks' infliximab, but with ongoing, varying levels of disease activity. They had to be willing to self-administer

2007 NHS Economic Evaluation Database.

138. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

139. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Full Text available with Trip Pro

Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Kaplan G G, Hur C, Korzenik J, Sands B E Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to determine if dose escalation of infliximab was cost-effective in comparison with adalimumab initiation after loss of response to infliximab in patients with Crohn’s disease. The authors concluded that dose escalation would yield more quality

2007 NHS Economic Evaluation Database.

140. Adalimumab - Arthritis, psoriatic

Adalimumab - Arthritis, psoriatic Common Drug Review CEDAC Meeting – October 18; 2006 Page 1 of 3 Notice of CEDAC Final Recommendation – November 29, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB RESUBMISSION (Humira ® - Abbott Laboratories Ltd.) Description: Adalimumab is a human monoclonal antibody to tumour necrosis factor (TNF). The Canadian Expert Drug Advisory Committee had previously recommended that adalimumab be listed for patients with moderate to severe (...) active rheumatoid arthritis who meet current drug plan criteria for funding of infliximab or etanercept (see Notice of CEDAC Final Recommendation on adalimumab issued on February 11, 2005). A new indication for use in psoriatic arthritis was the basis for the resubmission. Adalimumab is approved for reducing the signs and symptoms of active arthritis in adult psoriatic arthritis patients. Dosage Forms: 40 mg in 0.8 mL solution for subcutaneous injection. The recommended dose is 40 mg every two weeks

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review